Isabella Zampeta
Scientific Business Development Manager HUB Organoids (A Merck Company)
Seminars
Monday 12th October 2026
Target. Test. Treat: Enabling Smarter Evaluation of ADC Through Patient-Derived Organoids (PDOs)
10:30 am
- Leveraging PDOs as functional ADC patient avatars, preserving tumour heterogeneity and normal tissue biology to reflect clinical efficacy and toxicity
- Capturing ADC responses beyond antigen expression to assess target engagement, internalization, payload sensitivity, and tissue penetration
- Enabling development of next generation PDO therapeutic strategies to allow testing of combination therapies and comparison with SoC data
